Celgene reiterated by JMP at market outperform

Celgene Corp. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating and a $70 price target after the company presented data at a medical conference showing Revlimid's anticancer activity across several blood cancers. An update of a phase 3 study further confirms clinical and survival benefit of adding Revlimid to dexamethasone in patients with relapsed/refractory multiple myeloma. Shares of the Summit, N.J., pharmaceutical company were down 12 cents, or 0.20%, at $60.78 on volume of 1,004,831 shares versus the three-month running average of 2,490,710 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.